ABVC BioPharma (ABVC) Expected to Release Quarterly Earnings on Monday

ABVC BioPharma (NASDAQ:ABVC) is projected to issue its Q3 2026 resultson Monday, November 16th. Analysts expect the company to post earnings of ($0.40) per share and revenue of $0.11 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Monday, November 16, 2026 at 4:00 PM ET.

ABVC BioPharma (NASDAQ:ABVC) last posted its earnings results on Wednesday, August 12th. The company reported ($0.03) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.37.

ABVC BioPharma Price Performance

Shares of ABVC opened at $0.97 on Monday. The business’s 50-day moving average price is $1.01 and its 200-day moving average price is $1.24. ABVC BioPharma has a twelve month low of $0.71 and a twelve month high of $3.06. The stock has a market cap of $25.86 million, a PE ratio of -3.23 and a beta of 0.47.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of ABVC BioPharma in a research report on Friday, September 11th. One research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

About ABVC BioPharma

ABVC BioPharma, Inc (NASDAQ: ABVC) is a clinical-stage biopharmaceutical company focused on developing treatments for psychiatric and oncology-related conditions, as well as certain medical devices. The company advances product candidates through preclinical and clinical development and works with research, development and commercialization partners.

ABVC’s pipeline has included investigational therapies for major depressive disorder and other central nervous system conditions, along with oncology programs targeting cancer treatment.